European Patent Convention

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
Wednesday, November 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Retrieved on: 
Wednesday, November 1, 2023
Research, Patent, Inflammation, Prostate cancer, CPEO, Sonlicromanol, European Patent Office, MIDD, Reactive oxygen species, PGE2, MELAS, European Patent Convention, Patient, Mutation, Pharmaceutical industry

Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.

Key Points: 
  • Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.
  • The compound is currently under investigation for its effectiveness in treating adult patients diagnosed with primary mitochondrial disease due to the m.3243A>G mutation in their mitochondrial DNA.
  • This mutation is linked to various conditions such as classical MELAS and MIDD syndromes, CPEO, and mixed phenotypes.
  • These findings suggest a wider range of potential applications for sonlicromanol beyond its initial focus on primary mitochondrial diseases.

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Retrieved on: 
Wednesday, November 1, 2023
Research, Patent, Inflammation, Prostate cancer, CPEO, Sonlicromanol, European Patent Office, MIDD, Reactive oxygen species, PGE2, MELAS, European Patent Convention, Patient, Mutation, Pharmaceutical industry

Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.

Key Points: 
  • Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.
  • The compound is currently under investigation for its effectiveness in treating adult patients diagnosed with primary mitochondrial disease due to the m.3243A>G mutation in their mitochondrial DNA.
  • This mutation is linked to various conditions such as classical MELAS and MIDD syndromes, CPEO, and mixed phenotypes.
  • These findings suggest a wider range of potential applications for sonlicromanol beyond its initial focus on primary mitochondrial diseases.

3D Systems’ Co-founder & Chief Technology Officer, Chuck Hull, Awarded National Medal of Technology and Innovation

Retrieved on: 
Thursday, October 26, 2023
United Therapeutics, Science, 3D, National Inventors Hall of Fame, Regenerative medicine, Engineering, ROCK, Patent, NYSE, UV, Frost, White House, Mechanical engineering, 3D Systems, Analytik Jena, Carbon, Chicago Innovation Awards, ASME, Software, Society, UVP, Hull, SLA, National Medal of Technology and Innovation, Health, The, European Patent Convention, Patient, National Medal, American Society of Mechanical Engineers, European Inventor Award, 3D printing, Innovation, United, Stereolithography

Hull is being honored for the invention, development, and commercialization of Stereolithography (SLA), which launched the 3D printing industry, and for continuing innovation and leadership in additive manufacturing technology.

Key Points: 
  • Hull is being honored for the invention, development, and commercialization of Stereolithography (SLA), which launched the 3D printing industry, and for continuing innovation and leadership in additive manufacturing technology.
  • Hull applied for a patent for this technology, and in 1986 he co-founded 3D Systems through which the SLA-1, the first 3D printer, was commercialized.
  • He also received The Economist’s prestigious 2013 Innovation Award, recognizing significant contributions across the fields of science and technology.
  • “On behalf of the entire company, I congratulate Chuck as a recipient of the National Medal of Technology and Innovation,” said Dr. Jeffrey Graves, president & CEO, 3D Systems.

Medigene Reports Financial Results and Corporate Update for Q3 2023

Retrieved on: 
Thursday, October 26, 2023
Acceleration, IND, Patent, Innovation, ESMO, Logitech Driving Force GT, BioNTech, TCR, Platform, Congress, European Society for Medical Oncology, Intellectual property, KRAS, R, European Patent Office, Annual report, Kirsten, Partnership, CD28, EUR, Oncology, FSE, Senior, Therapy, European Patent Convention, IP, Patient, HLA, Frontiers, Rare-earth element, Pharmaceutical industry, Vaccine

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results and provided a corporate update for the third quarter of 2023.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results and provided a corporate update for the third quarter of 2023.
  • The Company’s Quarterly Statement Q3 2023 is available on Medigene’s website: https://medigene.com/investors-media/reports-presentations/
    “In the past quarter, we continued to successfully execute our corporate strategy and deliver on our commitments.
  • The Executive Management Board, therefore, maintains its guidance for the fiscal year 2023 published in the annual report 2022 on March 29, 2023, in its entirety.
  • Subsequent to the quarter, first pre-clinical data on MDG2011 was presented at the European Society for Medical Oncology (ESMO) Congress 2023 held in Madrid in October 2023.

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

Retrieved on: 
Thursday, October 26, 2023
Alternative Medicine, Mental Health, Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Patent, NYSE, IV, DSM-IV codes, Psilocybin, Inc., European Patent Office, DMT, NEO, European Patent Convention, Patient, Pharmaceutical industry

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs.
  • 4,031,529 provides composition of matter protection for certain deuterated tryptamine compounds, including deuterated psilocybin analogs within the CYB003 program and deuterated analogs of DMT within Cybin’s DMT program, as well as their medical use.
  • “Following quickly on from the two recently announced U.S. patents granted in respect of our deuterated DMT program, this European patent further strengthens our intellectual property protection around our deuterated DMT and deuterated psilocybin programs.
  • The Company expects to report topline data from its deuterated psilocybin and DMT programs in the fourth quarter of 2023.

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

Retrieved on: 
Thursday, October 19, 2023
Mental Health, Women, Seniors, Cannabis, Alternative Medicine, Health, Consumer, Pharmaceutical, Natural Resources, Patient, Ageing, The Journal of Pain, Patent, NYSE, Human, Pharma, Journal, Quality of life, IGC, European Patent Office, Peripheral nervous system, THC, Cannabinoid, Pain management, European Patent Convention, Cannabidiol, Arthritis, Pharmaceutical industry, CBD, Pain

IGC Pharma, Inc. (“IGC,” “IGC Pharma” or the “Company”) (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, is thrilled to announce a significant milestone: the grant of European Patent No.

Key Points: 
  • IGC Pharma, Inc. (“IGC,” “IGC Pharma” or the “Company”) (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, is thrilled to announce a significant milestone: the grant of European Patent No.
  • 3193862 by the European Patent Office (“EPO”) for our innovative "Cannabinoid Composition and Method for Treating Pain."
  • IGC Pharma is at the forefront of innovation, dedicated to enhancing the quality of life and well-being of those in pain.
  • Ram Mukunda, CEO of IGC Pharma, commented, “IGC Pharma is committed to advancing pain relief therapies rooted in decades of rigorous scientific research.

Anaconda Biomed Announces Additional Granted Patents for its Innovative Thrombectomy Device for Ischemic Stroke Treatment

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Biological patent, Stroke, European Patent Office, Disability, European Patent Convention, Blood vessel, Patient, Quality of life, Extraction, Pharmaceutical industry

The newly granted patents join a list of 17 issued patents for Anaconda Biomed, including “Thrombectomy Device And System For Extraction Of Vascular Thrombi From A Blood Vessel” in the United States with Patent No.

Key Points: 
  • The newly granted patents join a list of 17 issued patents for Anaconda Biomed, including “Thrombectomy Device And System For Extraction Of Vascular Thrombi From A Blood Vessel” in the United States with Patent No.
  • US 11,013,523 B2, among other key territories such as recently granted Canada and South Korea, together with Japan, China, Brazil, Taiwan and Australia.
  • The company’s growing patent portfolio demonstrates its dedication to innovation and unwavering mission to revolutionize stroke treatment worldwide.
  • "Every year, approximately 15 million people globally suffer from stroke,” said Richard Ferrari, Anaconda Biomed chairperson.

Allogeneic CAR Cell Therapy Market Surges in Response to Advancements in Gene Editing and IP Trends - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Health, Genetics, Other Science, Research, Science, Biotechnology, Patent, IP, IPSC, Abstract, Microsoft Excel, Traction, Graft-versus-host disease, Intellectual property, TALEN, Safety, Cancer, FDA, Allotransplantation, CRISPR, Growth, Database, European Patent Convention, CAR, Bone marrow, Gene editing, ZFN, NK, Attention, Vaccine, Pharmaceutical industry

The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.

Key Points: 
  • The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.
  • IP Trends Fuel Growth: The analysis of patent publications reveals that interest in allogeneic CAR therapies began in the late 2000s.
  • Advantages of Allogeneic CAR: Allogeneic CAR therapies offer several advantages over autologous CAR therapies, including faster production (10-11 days vs. over three weeks), scalability, standardization, and reduced manufacturing costs.
  • The report profiles key players in the allogeneic CAR cell therapy market, offering insights into their patent portfolios, geographical coverage, IP trends, and clinical trials.

NUVVE UPDATES ITS V2G PATENT PORTFOLIO

Retrieved on: 
Friday, October 13, 2023
Patent, United Kingdom, Disclosure, Original equipment manufacturer, EVS, Transport, EV, Growth, European Patent Convention, SAN, EPO, Manasantha Nuvve, EVE, Rail transport, Renewable energy, Online shopping, Fireworks

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Nuvve Holding Corp. (Nasdaq: NVVE) ("Nuvve"), a global technology leader accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) platform, today commented on its newly granted European patent.

Key Points: 
  • SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Nuvve Holding Corp. (Nasdaq: NVVE) ("Nuvve"), a global technology leader accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) platform, today commented on its newly granted European patent.
  • Since its inception in 2010, Nuvve has invested significant resources in growing its V2G patent portfolio – and continues to do so today.
  • During the span from 2011 to 2017, the company expanded its patent holdings to include four early-industry V2G patents in the U.S. Today, Nuvve has numerous later-filed U.S. patent applications pending.
  • As such, Nuvve's V2G patent portfolio serves as a solid foundation that is deeply rooted in the intelligent integration of EVs into the grid from a wide variety of system-level perspectives.